Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.60 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13599035 | 0.86 | MEN1 (0.64) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL31212424 | 0.83 | MEN1 (0.61) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL8564336 | 0.83 | MEN1 (0.83) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL14919477 | 0.82 | MEN1 (0.68) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL13598934 | 0.81 | HDAC3 (0.68) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL3974715 | 0.81 | EPHX2 (0.65) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL31212414 | 0.80 | MEN1 (0.64) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL6795564 | 0.80 | MEN1 (0.60) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL7216688 | 0.80 | KMT2A (0.97) | MEN1KMT2ACNR1EPHX2TSHR | |
| SCHEMBL3059602 | 0.79 | HTR7 (0.55) | MEN1KMT2AHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009054543-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR PARKINSON'S DISEASE AND MOVEMENT DISORDERS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009054544-A1 | AMPA RECEPTOR ANTAGONISTS FOR PARKINSON'S DISEASE AND MOVEMENT DISORDERS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-04-30 | — | — | WO | disclosed |
| US-7517991-B2 | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1814550-A2 | N-SULFONYLPIPERIDINE CANNABINOID RECEPTOR 1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006044362-A2 | N-SULFONYLPIPERIDINE CANNABINOID RECEPTOR 1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079556-A1 | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079556-A1 | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | CNR1, CNR2, NPY1R | MEN1 3281/4885KMT2A 3040/4885HDAC3 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.